FDA Probes Two Deaths Linked to Bootleg Weight-Loss Drug

The U.S. Food and Drug Administration has received reports that two people died after taking bootleg versions of retatrutide, an experimental weight-loss drug that has never been approved for human use, CBS News reported. The cases, obtained through a public records request and published on October 13, appear to be the first public U.S. accounts alleging that unauthorized use of the drug played a role in a patient’s death. Neither death has been verified as caused by the drug, and the FDA has redacted identifying details.

What the Reports Describe

The first report reached the FDA in July 2026. According to CBS News, a healthcare professional informed the agency that a 41-year-old woman with obesity went into cardiac arrest and died after obtaining retatrutide “from an unreliable source.” The report listed the drug as a “suspect product.”

The second report, received in September, described a 49-year-old patient who died after a licensed nurse “convinced” her to buy retatrutide from an online peptide vendor. The nurse, whose name, location and license number were redacted, allegedly “provided her the link and sold her vials and provided recommended dosages.” The patient suffered severe dehydration, malnutrition and cardiac arrest.

The FDA declined to say whether it had verified any information in either report. “We review adverse event reports, gathering additional information when needed,” the agency said, adding that it “generally does not discuss potential or ongoing compliance matters.” CBS News said it could not independently verify the reports, which were submitted to the FDA’s Adverse Event Reporting System and redacted to remove details identifying the people involved.

A Booming Black Market

Retatrutide — often called “Reta,” “r3ta” or “GLP-3” — is a triple hormone receptor agonist developed by Eli Lilly that targets the GLP-1, GIP and glucagon receptors. It is being studied in Phase 3 clinical trials for obesity, type 2 diabetes and related conditions, and has not been approved by any regulatory agency worldwide. Because it was never on the FDA’s drug-shortage list, it is not eligible for pharmacy compounding, meaning every vial sold outside a Lilly-sponsored trial is, by definition, bootleg.

That has not stopped a sprawling online market. A June 2026 Public Citizen report found that more than 100 companies openly sell retatrutide, marketed with “research use only” disclaimers while being pitched to consumers as a weight-loss shortcut. Of 179 retatrutide vendors rated by the testing company Finnrick, 71 — nearly 40 percent — were classified as “poor,” “bad” or “fraud.”

Harm reports are climbing fast. America’s Poison Centers logged 862 retatrutide exposures in the three months ending in September 2026, up from 460 in the prior quarter and 249 in the first quarter of the year — roughly a 3.5-fold rise in six months. Public Citizen, citing FDA data, found 26 adverse-event reports in the first five months of 2026 alone, including 11 hospitalizations and three cases described as “life-threatening.”

The Regulatory Gap

Federal law prohibits the commercial sale of unapproved drugs, but enforcement has largely stopped at warning letters. Since December 2024, the FDA has sent 14 warning letters to companies selling retatrutide. Public Citizen found that as of May 2026, 11 of those 14 sellers continued to advertise retatrutide or other unapproved peptides, and eight were still selling retatrutide itself. One of the letter recipients, Pink Pony Peptides, told customers on TikTok a month after receiving its warning that it was “still in action.”

“The FDA is clearly not addressing the problem,” Gerard Olson, research director at the internet-certification firm LegitScript, told Public Citizen. “Out on the internet you can’t throw a stone without hitting [a peptide vendor]. We see a lot of retatrutide.”

Pieter Cohen, an associate professor at Harvard Medical School, told CBS News that the agency should aggressively pursue the cases. “The FDA should do whatever it possibly could do to get their hands on the actual drug that was injected by both of these patients, and they should get that analyzed,” he said. “If the FDA is not aggressively investigating these cases, that’s deeply concerning.”

Tougher measures — seizures, injunctions and criminal prosecutions — require coordination with the Department of Justice and additional resources. Critics argue the agency has been slow to use them even as the market and reported injuries grow.

Lilly Escalates Its Own Fight

Eli Lilly, which plans to file for FDA approval of retatrutide in early 2027, has taken its own legal action. In August 2026, the company filed six new lawsuits against U.S. entities selling black-market products, including compounding pharmacies, medical spas and online sellers. Lilly said it has referred more than 200 individuals and entities to regulators and law enforcement and reported more than 14,000 illicit listings across over 100 countries.

“What is being sold on the black market is not a medicine — it is entirely unverified, unapproved and not worth the risk,” said David A. Hyman, Lilly’s chief medical officer. The company has called on social media platforms, payment processors and shipping companies to cut off the infrastructure enabling the trade.

In the September case, an image in the FDA report showed a vial labeled “AlphaLabs.” Joseph Samara, who applied for the Alpha Labs trademark earlier this year, initially told CBS News “we don’t sell retatrutide” before hanging up. His attorney, Sinead Killeen, later said there was not enough information in the redacted report to determine whether the company sold the product, and that the vial image “does not match the company’s current packaging.” She added that “a licensed healthcare professional should never recommend research-use-only products to a patient” and said the company would support a review of the nurse’s conduct.

What to Watch

With retatrutide’s approval still months away and no lawful supply outside clinical trials, the black market is likely to keep growing — and so are the reports of harm. The central questions now are whether the FDA will move beyond warning letters to seizures or prosecutions, and whether the two reported deaths prove to be linked to the drug or to contaminants and dosing errors in unverified vials.

For patients, the message from regulators and the manufacturer is consistent: no product claiming to be retatrutide should be used outside a supervised clinical trial. As the investigations continue, the cases stand as a warning about what happens when demand for an unapproved drug outruns the system meant to keep it off the market.